



- (51) **International Patent Classification:**
A61M 15/00 (2006.01) A61M 16/00 (2006.01)
- (21) **International Application Number:**
PCT/US2024/010925
- (22) **International Filing Date:**
09 January 2024 (09.01.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/437,909 09 January 2023 (09.01.2023) US
- (71) **Applicant: PNEUMA RESPIRATORY, INC.** [US/US];
870 State Farm Rd., Suite 103-B, Boone, North Carolina 28607 (US).
- (72) **Inventors: HUNTER, Charles Eric;** 870 State Farm Rd., Suite 103-B, Boone, North Carolina 28607 (US). **RAPP, Gregory;** 870 State Farm Rd., Suite 103-B, Boone, North Carolina 28607 (US).
- (74) **Agent: HANSON, Eric J. et al.;** Polsinelli PC, PO Box 140310, Kansas City, Missouri 64114-0310 (US).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** DROPLET DELIVERY DEVICE WITH HIGH DOSE CONFIDENCE MODE




FIG. 1

(57) **Abstract:** A droplet delivery device includes a high dose confidence mode that monitors a user's inhalation of a composition and activates and deactivates aerosol generation via monitoring the user's inhalation to assist the user to complete a full dosage when a user does not inhale a full dosage of the composition when using the device.

WO 2024/151663 A1

Published:

— *with international search report (Art. 21(3))*

DROPLET DELIVERY DEVICE WITH HIGH DOSE CONFIDENCE MODE**CROSS-REFERENCE TO RELATED APPLICATIONS**

[0001] This application claims the benefit of priority of U.S. Provisional Application No. 63/437,909, entitled “Droplet Delivery Device with High Dose Confidence Mode,” filed January 9, 2023, which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

[0002] This disclosure relates to droplet delivery devices and more specifically to droplet delivery devices for the delivery of fluids that are inhaled into mouth, throat, nose, and/or lungs. While the present invention particularly pertains to the delivery of therapeutic compositions, in some embodiments non-therapeutic compositions that are capable of being aerosolized could also be used.

BACKGROUND

[0003] The present application incorporates herein by reference in their entirety the contents of WO 2020/264501 (describing “Ring Mode” ejection), PCT/US2022/034552 (describing “Push Mode” ejection), U.S. Pat. No. 10,449,314 (describing dose verification) and US Patent Application Pub. No. 20190134330 (describing user feedback and instructions).

[0004] There is a need for droplet delivery devices, such as those devices described in Applicant’s referenced patent publications, to measure dosage throughout the administration/inhalation process of a patient to provide a high dose confidence mode of proper dosage being administered to the patient. Specifically, the present invention can determine if a patient does not receive the full dose initially and the device calculates the remaining dosage and gives the patient a voice command, visual notification, or similar communication to inhale again to complete the dosage.

[0005] SUMMARY OF THE INVENTION

[0006] Droplet delivery devices of the present invention, such as for inhaling medicines, pharmaceuticals, biologics, vaccines, and other therapeutic substances, use a differential pressure sensor to measure the user’s inhalation profile over the course of a dosage. In some embodiments, a Sensirion SDP3x™ sensor (available from Sensirion AG located at Laubisruestrasse 50, 8712 Stäfa, Switzerland, with a U.S. location/affiliate of Sensirion Connected Solutions Inc., 11 East Adams Suite 220, Chicago, IL 60603), which has a pressure

update rate of 0.5 milliseconds and accuracy of 0.1 Pa and is included in a droplet delivery device to measure the user's inhalation profile near real time.

[0007] In an embodiment, a user initiates their dosage by inhaling from the mouthpiece of a droplet deliver device. Upon inhalation, the device begins actuating an ejector member, such as piezoelectric element/transducer in combination with a mesh or plate with apertures to generate aerosol – such as a piezoelectric transducer in “Push Mode” ejection devices and piezoelectric elements in “Ring Mode” ejection devices (disclosed by incorporation by reference herein). If the patient stops inhaling from the mouthpiece before their metered dosage is complete, the device will stop generating aerosol. The device will then wait until the patient is inhaling from the mouthpiece to deliver the remaining dosage.

[0008] For example, if a user's dosage requires a 1.5 second inhalation and they stop inhaling halfway at 0.75 seconds, they still need to take the other half of their dosage. Droplet devices of the present invention sense that a remaining amount of dosage is yet to be completed and stop generating aerosol then prompt the user that they did not receive their entire dosage and instruct them to inhale from the mouthpiece again. When the user initiates the spray for the second time, the device will begin to generate aerosol and continue until the other half of their dosage is inhaled. It will be appreciated that remaining dosage and aerosol generation of time for the remaining amount of dosage can be any difference amount between a full dosage and the amount the user inhaled (e.g., based on time) during the initial administration event.

BRIEF DESCRIPTION OF THE DRAWINGS

[0009] FIG. 1 illustrates a relational block diagram of a droplet device components and microcontroller unit (MCU) in one embodiment of the present invention.

DETAILED DESCRIPTION

[0010] With reference to FIG. 1, the MCU 100 reads all switches and sensors and controls all primary functions including piezo waveform generation, dose and user interface (UI) display, voice prompts, chip ID read and user compliance archiving. Main MCU 100 activates when the digital power is initiated by the Power MCU 175 and holds digital power on. On/Off Switch 120 may be closed when the mouth cap opens to initiate power and readiness of the device to provide aerosol generation. A battery test 135 may also be operably connected to the MCU 100.

[0011] The total inhalation time is determined by the drug application. Droplet devices of the present invention are metered to a specific drug dispense rate, and depending on that parameter the total inhalation time may be determined. The predetermined dosage time is then specified in the software of the microcontroller to provide the high dose confidence mode.

Cartridge ID resistor 110 may provide different resistances to identify different liquid supply cartridges so that the corresponding dosage, including dispense rate and inhalation time, is determined for the corresponding drug application.

[0012] In some embodiments, drug efficacy can be calculated through some combination of the instantaneous flow rate from the user and the amount of time inhaled. For example, if a user was inhaling at sufficient flow rate for the full dosage time the drug efficacy would be 100%. If the user was inhaling at a less than sufficient flow rate for the full dosage time the drug efficacy less than 100%. If the user was inhaling at a sufficient flow rate for half the dosage time the drug efficacy would be 50%. The device could then allow for a successive administration to deliver the remaining portion of their dosage.

[0013] The timing of the start/stop method is a timer program of the microcontroller based on the pressure change measured from the pressure sensor 105. The droplet delivery device begins actuating the piezoelectric element/transducer with piezo driver IC 155 and starts a timer via clock IC 150 when the system notices a drop in pressure from a user inhaling on the mouthpiece and sense by pressure sensor 105. The device then stops the timer via clock IC 150 and stops piezo element/transducer actuation after the pressure sensor value sensed from sensor 105 drops below an accepted value. The delay from when the user starts inhaling to the device actuating the spray can be less than or equal to 0.5 milliseconds due to the measurement time on the Sensirion™ pressure sensor 105. The delay from when the dosage timer starts to when the piezoelectric is actuated is much less, on the scale of microseconds.

[0014] The pressure sensor 105 may be calibrated, for example, by using the standard 3L syringe for spirometry described at <https://www.a-msystems.com/p-60-fixed-volume-calibration-syringe.aspx> (incorporated herein by reference). The start/stop condition may be triggered by any of the following (which could be useful to ensure drug delivery to specific sections of the lung):

[0015] (1) Instantaneous pressure threshold - Either the user stops inhaling entirely or the user could not be inhaling with a sufficient flow rate; and

[0016] (2) A threshold for the volume of air or some other calculated value could be used for the start/stop condition.

[0017] In some embodiments, a communication or notification may be provided to the user that there is still a remaining amount of dosage necessary to reach full dosage. The user may be prompted, such as by an audio speaker communicating with sound chip 115 or visual notification, to again inhale on the device to finish administering the dosage. Voice switch increase 125 and voice switch decrease 130 inputs permit the user to adjust volume of the audio

from the speaker. Visual notifications to communicate user actions and device readiness are provided to the user by LED indicators 160, such as tricolor LEDs, and power status is signified by a battery LED indicator 165. An LCD Driver 170 may display a dose counter or similar indications of dosage administered and/or remaining to the user.

[0018] The piezo element/transducer is subsequently actuated for the remaining amount of dosage time (i.e., delivering the remaining amount to reach full dosage based on the calculated time that is remaining to reach full dosage) on detection of another pressure drop from the pressure sensor when the user inhales to complete the dosage. The microcontroller will deactivate the piezoelectric element after the remaining duration of inhalation to reach full dosage is completed by user.

[0019] The trickle-charge real time clock circuit 150 is important for Internet Of Things (IOT) applications (with paired mobile/desktop application such as via Bluetooth module 140) as it would enable each dosage to be accurately tracked in real time. This circuit can use a very small amount of power to keep a clock running on the device even while the device is completely powered off.

[0020] There are at least two alternatives that can be used to drive the piezo element/transducer. A first alternative is that the piezoelectric element/transducer is driven by a waveform generated by a boost converter, H-bridge circuit. The second alternative is an autotransformer and MOSFET circuit 180. These both work similarly to one another in that a frequency generated by the microcontroller pulse width modulation or a separate integrated circuit determines the frequency of the waveform applied to the piezo element/transducer. The alternatives differ in how they generate high voltage (>30V). The ejection start, or actuation of the piezoelectric element/transducer, is initiated by the microcontroller in software by either sending a PWM to a MOSFET or I2C signal to a frequency generator chip. The ejection stop, or deactivation of the piezoelectric element/transducer, is initiated by either stopping the PWM to a MOSFET or send another I2C signal to the frequency generator chip.

[0021] A Bluetooth module 140 may be provided in embodiments to permit communication with smart devices, such as smartphones, for tracking dosage administration and/or other data associated with the user and device via a Bluetooth-enabled application running on the smart device. Data received by the application may be communicated to a network (such as via an Internet connection), including processing such data to provide resulting messages and information about the user's treatments, compliance, dosage, and use of the device to a healthcare provider or patient/individual monitoring service. An accelerometer 145 may also be operable connected to the MCU 100 to provide orientation and

tilting information for the device that might could necessitate change the dosage calculations or trigger notification to the user to adjust how the device is positioned to optimize the delivery of a drug application.

[0022] While piezotronics are described in embodiments of the invention, including specific types and brands of electronics, it will be appreciated that other elements may be utilized as transducers to provide vibrating functionality to an ejector for aerosol generation. Similarly, although specific data communication protocols (I2C, SPI, etc) are described or illustrated in certain embodiment of the invention, it will be appreciated by those skill in the relevant art that a variety of other data communication protocols could be applied with the same effect.

[0023] Various embodiments of the invention have been described. It will, however, be evident that various modifications and changes may be made thereto, and additional embodiments may be implemented, without departing from the broader scope of the invention as set forth by the disclosure. This specification is to be regarded in an illustrative rather than a restrictive sense.

What is Claimed:

1. A droplet delivery device comprising:
a vibrating ejector member coupled to a supply of a composition; and
a dosage monitor that powers the vibrating ejector member on and off based on a user's incomplete inhalation of a full dosage of the composition.
2. The device of claim 1, further comprising a pressure sensor in communication with a microcontroller of the device, wherein the microcontroller turns the vibrating ejector member on and off based on a pressure value of a user's inhalation relative to the device.
3. The device of claim 2, further comprising a speaker in communication with the microcontroller to provide audible notification to the user of a remaining dosage necessary to complete administration of the full dosage of the composition.
4. The device of claim 3, further comprising a display or light in communication with the microcontroller to provide visual notification to the user of a remaining dosage necessary to complete administration of the full dosage of the composition.
5. The device of claim 2, further comprising a display or light in communication with the microcontroller to provide visual notification to the user of a remaining dosage necessary to complete administration of the full dosage of the composition.
6. The device of claim 1, further comprising a liquid supply cartridge having an identifier that communicates the full dosage parameters for the composition corresponding to the liquid supply cartridge to the dosage monitor.
7. The device of claim 2, further comprising a liquid supply cartridge having an identifier that communicates the full dosage parameters for the composition corresponding to the liquid supply cartridge to the microcontroller.
8. The device of claim 3, further comprising a liquid supply cartridge having an identifier that communicates the full dosage parameters for the composition corresponding to the liquid supply cartridge to the microcontroller.

9. The device of claim 4, further comprising a liquid supply cartridge having an identifier that communicates the full dosage parameters for the composition corresponding to the liquid supply cartridge to the microcontroller.
10. The device of claim 5, further comprising a liquid supply cartridge having an identifier that communicates the full dosage parameters for the composition corresponding to the liquid supply cartridge to the microcontroller.
11. The device of claim 2, wherein the microcontroller is programmed to calculate drug efficacy and determine a remaining dosage necessary to complete administration of the full dosage of the composition by detecting from the pressure sensor during the user's inhalation a combination of instantaneous flow rate and amount of time inhaled.
12. The device of claim 3, wherein the microcontroller is programmed to calculate drug efficacy and determine a remaining dosage necessary to complete administration of the full dosage of the composition by detecting from the pressure sensor during the user's inhalation a combination of instantaneous flow rate and amount of time inhaled.
13. The device of claim 4, wherein the microcontroller is programmed to calculate drug efficacy and determine a remaining dosage necessary to complete administration of the full dosage of the composition by detecting from the pressure sensor during the user's inhalation a combination of instantaneous flow rate and amount of time inhaled.
14. The device of claim 5, wherein the microcontroller is programmed to calculate drug efficacy and determine a remaining dosage necessary to complete administration of the full dosage of the composition by detecting from the pressure sensor during the user's inhalation a combination of instantaneous flow rate and amount of time inhaled.
15. The device of claim 7, wherein the microcontroller is programmed to calculate drug efficacy and determine a remaining dosage necessary to complete administration of the full dosage of the composition by detecting from the pressure sensor during the user's inhalation a combination of instantaneous flow rate and amount of time inhaled.

16. The device of claim 8, wherein the microcontroller is programmed to calculate drug efficacy and determine a remaining dosage necessary to complete administration of the full dosage of the composition by detecting from the pressure sensor during the user's inhalation a combination of instantaneous flow rate and amount of time inhaled.
17. The device of claim 9, further comprising a liquid supply cartridge having an identifier that communicates the full dosage parameters for the composition corresponding to the liquid supply cartridge to the microcontroller.
18. The device of claim 10, further comprising a liquid supply cartridge having an identifier that communicates the full dosage parameters for the composition corresponding to the liquid supply cartridge to the microcontroller.
19. A droplet delivery device comprising:
a vibrating ejector member coupled to a supply of a composition;
a transducer coupled the vibrating ejector member; and
a microcontroller that powers the transducer on and off based on a user's incomplete inhalation of a full dosage of the composition.
20. The device of claim 19, further comprising a pressure sensor in communication with the microcontroller, wherein the microcontroller automatically turns the transducer on and off based on a pressure value of a user's inhalation relative to the device.




FIG. 1

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2024/010925

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61M15/00 A61M16/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2014/184006 A1 (KONINKL PHILIPS NV [NL]) 20 November 2014 (2014-11-20) figures 1-17 page 8, line 1 - page 18, line 30 -----	1-20
X	WO 2018/107018 A1 (MICRODOSE THERAPEUTX INC [US]) 14 June 2018 (2018-06-14) figures 1-6 paragraph [0016] - paragraph [0033] -----	1-20
X	WO 2019/195239 A1 (PNEUMA RESPIRATORY INC [US]) 10 October 2019 (2019-10-10) figures 1-11 page 7, line 29, paragraph 47 - page 27, line 14, paragraph 51 -----	1-20
	-/--	

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

10 April 2024

18/04/2024

Name and mailing address of the ISA/
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040,
 Fax: (+31-70) 340-3016

Authorized officer

Liess, Helmar

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2024/010925

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2020/261665 A1 (PELL DONALD M [US] ET AL) 20 August 2020 (2020-08-20) figure 1 paragraph [0009] - paragraph [0020] -----	1-20
X	WO 2020/219012 A1 (SUNOVION PHARMACEUTICALS INC [US]) 29 October 2020 (2020-10-29) figures 1-10 paragraph [0046] - paragraph [0085] -----	1-20
X	US 2017/319797 A1 (GERMINARIO LOUIS THOMAS [US] ET AL) 9 November 2017 (2017-11-09) figures 1-11 paragraph [0065] - paragraph [0105] -----	1-20

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/US2024/010925
--

Patent document cited in search report	Publication date	Patent family member(s)	Publication date		
WO 2014184006	A1	20-11-2014	CN 105209097 A 30-12-2015		
			EP 2996748 A1 23-03-2016		
			JP 6506257 B2 24-04-2019		
			JP 2016517785 A 20-06-2016		
			RU 2015153936 A 22-06-2017		
			US 2016121057 A1 05-05-2016		
			WO 2014184006 A1 20-11-2014		

WO 2018107018	A1	14-06-2018	AU 2017370741 A1 20-06-2019		
			BR 112019011843 A2 20-08-2019		
			CA 3046359 A1 14-06-2018		
			CN 110167618 A 23-08-2019		
			EA 201991386 A1 29-11-2019		
			EP 3551260 A1 16-10-2019		
			ES 2886974 T3 21-12-2021		
			IL 267110 A 29-08-2019		
			JP 2020500632 A 16-01-2020		
			KR 20190092517 A 07-08-2019		
			US 2020030553 A1 30-01-2020		
			WO 2018107018 A1 14-06-2018		

			WO 2019195239	A1	10-10-2019
US 2021106772 A1 15-04-2021					
WO 2019195239 A1 10-10-2019					

US 2020261665	A1	20-08-2020	NONE		

WO 2020219012	A1	29-10-2020	CA 3132941 A1 29-10-2020		
			EP 3958940 A1 02-03-2022		
			JP 7461374 B2 03-04-2024		
			JP 2022536584 A 18-08-2022		
			JP 2023129716 A 14-09-2023		
			WO 2020219012 A1 29-10-2020		

US 2017319797	A1	09-11-2017	AU 2017259982 A1 29-11-2018		
			AU 2017260444 A1 20-12-2018		
			AU 2019210668 A1 22-08-2019		
			CA 3022916 A1 09-11-2017		
			CA 3022918 A1 09-11-2017		
			CN 109414178 A 01-03-2019		
			CN 109475707 A 15-03-2019		
			CN 109475709 A 15-03-2019		
			EP 3451905 A1 13-03-2019		
			EP 3452150 A1 13-03-2019		
			EP 3452152 A1 13-03-2019		
			IL 262735 A 31-12-2018		
			JP 6774508 B2 28-10-2020		
			JP 7072554 B2 20-05-2022		
			JP 7407593 B2 04-01-2024		
			JP 2019514656 A 06-06-2019		
			JP 2019515764 A 13-06-2019		
			JP 2019523109 A 22-08-2019		
			JP 2020054847 A 09-04-2020		
			JP 2021130013 A 09-09-2021		
			JP 2022188270 A 20-12-2022		
			JP 2023093609 A 04-07-2023		
			KR 20190004763 A 14-01-2019		
			KR 20200070425 A 17-06-2020		

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2024/010925

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		US 2017319796 A1	09-11-2017
		US 2017319797 A1	09-11-2017
		US 2018344955 A1	06-12-2018
		US 2018369515 A1	27-12-2018
		US 2019117907 A1	25-04-2019
		US 2019125985 A1	02-05-2019
		US 2019125986 A1	02-05-2019
		US 2019125987 A1	02-05-2019
		US 2019134330 A1	09-05-2019
		US 2019358420 A1	28-11-2019
		US 2021236745 A1	05-08-2021
		US 2022008669 A1	13-01-2022
		US 2023277781 A1	07-09-2023
		WO 2017192767 A1	09-11-2017
		WO 2017192771 A1	09-11-2017
		WO 2017192773 A1	09-11-2017
		WO 2017192774 A1	09-11-2017
		WO 2017192778 A1	09-11-2017
		WO 2017192782 A1	09-11-2017
